DexCom (DXCM) Soars 5.6%: Is Further Upside Left in the Stock?

Company Performance - The medical device company is expected to report quarterly earnings of $0.52 per share, reflecting a year-over-year increase of +4% [1] - Revenues are anticipated to reach$ 1.1 billion, which is a 5.9% increase compared to the same quarter last year [1] - For Edwards Lifesciences, the consensus EPS estimate has been adjusted to $0.55, indicating a -14.1% change from the previous year [3] Stock Movement - DexCom shares increased by 5.6% in the last trading session, closing at$ 80.04, with notable trading volume [2] - Edwards Lifesciences closed 1.2% higher at $74.81, with a 5% return over the past month [5] - The positive trend in earnings estimate revisions for DexCom suggests potential price appreciation in the future [7] Industry Context - The rise in DexCom's stock is linked to Novo Nordisk's disappointing results from its weight-loss drug study, which shifted investor sentiment favorably towards diabetes device companies [6] - The Zacks Medical - Instruments industry includes both DexCom and Edwards Lifesciences, with both companies currently holding a Zacks Rank of 3 (Hold) [2][3]